Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration
Authors
Keywords
Vascular Endothelial Growth Factor, Bevacizumab, Ranibizumab, Endophthalmitis, Vascular Endothelial Growth Factor Level
Journal
DRUG SAFETY
Volume 38, Issue 3, Pages 279-293
Publisher
Springer Nature
Online
2015-02-21
DOI
10.1007/s40264-015-0273-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
- (2015) Karina Berg et al. OPHTHALMOLOGY
- Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration
- (2014) Izumi Yoshida et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
- (2014) Allen C. Ho et al. OPHTHALMOLOGY
- Meta-Analysis of Infectious Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents
- (2014) John B. Fileta et al. Ophthalmic Surgery Lasers & Imaging Retina
- A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
- (2013) Ilse Krebs et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema
- (2013) Claus Zehetner et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
- (2013) K Ghasemi Falavarjani et al. EYE
- Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
- (2013) Usha Chakravarthy et al. LANCET
- Streptococcus Endophthalmitis Outbreak after Intravitreal Injection of Bevacizumab: One-Year Outcomes and Investigative Results
- (2013) Roger A. Goldberg et al. OPHTHALMOLOGY
- Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial
- (2013) Laurent Kodjikian et al. OPHTHALMOLOGY
- Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
- (2013) Juan E. Grunwald et al. OPHTHALMOLOGY
- Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
- (2013) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- Aflibercept in wet AMD: specific role and optimal use
- (2013) Francesco Semeraro et al. Drug Design Development and Therapy
- An Outbreak of Fungal Endophthalmitis After Intravitreal Injection of Compounded Combined Bevacizumab and Triamcinolone
- (2013) Alan T. Sheyman et al. JAMA Ophthalmology
- Age-related macular degeneration
- (2012) Laurence S Lim et al. LANCET
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2012) Daniel F. Martin et al. OPHTHALMOLOGY
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
- (2012) Usha Chakravarthy et al. OPHTHALMOLOGY
- Acute Intraocular Inflammation Caused by Endotoxin after Intravitreal Injection of Counterfeit Bevacizumab in Shanghai, China
- (2012) Fenghua Wang et al. OPHTHALMOLOGY
- CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION
- (2012) Raul Velez-Montoya et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab
- (2011) Ângela M. Carneiro et al. ACTA OPHTHALMOLOGICA
- Sustained Increased Intraocular Pressure Related to Intravitreal Antivascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration
- (2011) Joseph J. Tseng et al. JOURNAL OF GLAUCOMA
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
- (2011) Frank G. Holz et al. OPHTHALMOLOGY
- Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents
- (2011) Chirag P. Shah et al. OPHTHALMOLOGY
- META-ANALYSIS OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
- (2011) Colin A Mccannel RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
- (2011) Michael Tolentino SURVEY OF OPHTHALMOLOGY
- Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections
- (2010) Carsten H. Meyer et al. ACTA OPHTHALMOLOGICA
- Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration
- (2010) Lesley H. Curtis ARCHIVES OF OPHTHALMOLOGY
- Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab
- (2010) K. Matsuyama et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents
- (2010) T. J. Good et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Effect of Brimonidine/Timolol Fixed Combination on Preventing the Short-Term Intraocular Pressure Increase after Intravitreal Injection of Ranibizumab
- (2010) P. Theoulakis et al. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
- (2010) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- CLINICAL CHARACTERISTICS OF ENDOPHTHALMITIS AFTER AN INJECTION OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
- (2010) Daphna Mezad-Koursh et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Clinical safety of ranibizumab in age-related macular degeneration
- (2009) Ursula Schmidt-Erfurth Expert Opinion On Drug Safety
- Short-term Effect of Intravitreal Injection of Ranibizumab (Lucentis) on Intraocular Pressure
- (2009) Maurizio Gismondi et al. JOURNAL OF GLAUCOMA
- Sustained Elevation in Intraocular Pressure Associated with Intravitreal Bevacizumab Injections
- (2009) Malik Y. Kahook et al. OPHTHALMIC SURGERY LASERS & IMAGING
- Large Subretinal Haemorrhage following Change from Intravitreal Bevacizumab to Ranibizumab
- (2009) Dimitrios A. Karagiannis et al. OPHTHALMOLOGICA
- A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
- (2009) David S. Boyer et al. OPHTHALMOLOGY
- SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB
- (2009) IOANNIS D. LADAS et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
- (2008) Carl D. Regillo et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB
- (2008) DAVID R. FINTAK et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now